

Alexandra (Alex) Wood

Associate

London

Biography

Alex is an associate in our Pharmaceutical and Biotechnology team. Alex advises life science companies on a wide range of regulatory matters, including clinical trial requirements, early access schemes, marketing authorisations, manufacturing and distribution licences, supply chain issues, CE / UKCA marking, product labelling, advertising and marketing activities, non-promotional activities, pricing and reimbursement and distinctions between Great Britain and Northern Ireland in pharmaceutical and medical device law since Brexit. Alex also advises on international commercial transactions in the life sciences sectors, including complex clinical / commercial agreements spanning the life cycle of medicinal products / medical devices, collaboration, manufacturing, distribution, warehousing, services, quality and pharmacovigilance agreements, as well as other commercial contractual arrangements, including consultancy, sponsorship, co-promotion and joint working agreements.

Representative experience

Advising various multinational pharmaceutical companies on the regulatory requirements relating to marketing authorisations and manufacturing, import and wholesale dealer licences.

Drafting and negotiating various manufacturing and distribution arrangements for leading pharmaceutical companies.



Phone

07821682553

Fax

+44 20 7296 2001

Email

alexandra.wood@hoganlovells.com

Practices

Pharmaceuticals and Biotechnology
Regulatory

Industries

Life Sciences and Health Care

Education and admissions

Education

Bachelor of Laws with Honours
(LLB), University of Cape Town,
2016

Bar admissions and qualifications

South Africa

Drafting clinical trial agreements, master services agreements and related standard operating procedures for a leading CRO.

Advising various pharmaceutical companies on the acquisition / divestment of product portfolios and drafting / advising on the related sale and transitional agreements.

Latest thinking and events

- News
 - CMA issues statement on permitted collaboration to assist provision of combination therapies to NHS